Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20214289 | 1.00 | NAMPT (0.52) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL18509855 | 0.99 | NAMPT (0.53) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL379486 | 0.99 | NAMPT (0.53) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL4372297 | 0.99 | NAMPT (0.53) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Bromide SCHEMBL11455325 | 0.98 | NAMPT (0.52) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL4953654 | 0.95 | NAMPT (0.49) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL4953664 | 0.95 | NAMPT (0.49) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL5172065 | 0.88 | F2 (0.51) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Glycyl Proline SCHEMBL28466633 | 0.85 | F2 (0.48) | LMNAMMP2MMP9ALDH1A1EPHX2 | |
| SCHEMBL28579566 | 0.85 | LMNA (0.48) | LMNAMMP2MMP9ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12575589-B2 | Chia seed derived products and the process thereof | PURDUE RESEARCH FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4698629-A1 | DERIVATION OF PRIMARY EPITHELIAL ORGANOIDS | UCL Business Ltd (GB) | 2026-02-25 | — | — | EP | disclosed |
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| CN-119019492-B | Spirulina source natural DPP-IV inhibitory peptide and preparation method and application thereof | 中国科学院烟台海岸带研究所 | 2025-01-28 | — | — | CN | disclosed |
| US-20240415155-A1 | CHIA SEED DERIVED PRODUCTS AND THE PROCESS THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2024-12-19 | — | — | US | disclosed |
| CN-119019492-A | Spirulina source natural DPP-IV inhibitory peptide and preparation method and application thereof | 中国科学院烟台海岸带研究所 | 2024-11-26 | — | — | CN | disclosed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | disclosed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024218496-A1 | DERIVATION OF PRIMARY EPITHELIAL ORGANOIDS | UCL BUSINESS LTD (GB) | 2024-10-24 | — | — | WO | disclosed |
| CN-118599817-A | Recombinant DPP4 and preparation method thereof, DNA fragment, recombinant vector, recombinant cell and recombinant escherichia coli | 深圳大学 | 2024-09-06 | — | — | CN | disclosed |
| US-11805795-B2 | Chia seed derived products and the process thereof | PURDUE RESEARCH FOUNDATION (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116790434-A | Lactobacillus pentosus and application thereof in preparation of sugar metabolism regulator | 中国海洋大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-113425747-A | Application of bacillus coagulans JA845 in preparation of enzyme activity inhibitor with hypoglycemic function | 吉林省农业科学院 | 2021-09-24 | — | — | CN | disclosed |
| CN-108048489-B | Method for preparing DPP-IV inhibitor by using Paenibacillus polymyxa and prepared DPP-IV inhibitor | 光明乳业股份有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3107556-B1 | COMPOSITIONS FOR PREVENTING AND/OR TREATING PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALPHA-GLUCOSIDASE | UNIV LA ROCHELLE (FR) | 2019-04-10 | — | — | EP | disclosed |
| US-20180104303-A1 | COMPOSITIONS FOR PREVENTING AND/OR TREATING PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALPHA-GLUCOSIDASE | UNIVERSITE CLERMONT AUVERGNE (FR) | 2018-04-19 | — | — | US | disclosed |
| EP-3107556-A1 | COMPOSITIONS FOR PREVENTING AND/OR TREATING PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALPHA-GLUCOSIDASE | Universite De La Rochelle (FR) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015124867-A1 | COMPOSITIONS FOR PREVENTING AND/OR TREATING PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALPHA-GLUCOSIDASE | Université de la Rochelle (FR) | 2015-08-27 | — | — | WO | disclosed |
| US-20080050460-A1 | Uses of lectin-conotoxin | SAVIDGE TOR C | 2008-02-28 | — | — | US | disclosed |
| WO-2007146185-A2 | USES OF LECTIN-CONOTOXIN | SAVIDGE TOR C (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12575589-B2 | Chia seed derived products and the process thereof | CHIA, CHI3L1, CHI3L2 | GAA 164/4885NAMPT 3516/4885LMNA 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.